On January 11, the Centers for Medicare and Medicaid Services (CMS) announced its much-anticipated coverage proposal for monoclonal antibody treatments that target amyloid for the treatment of Alzheimer’s disease. According to the proposed policy, this class of drugs, which includes aducanumab, also known by the brand name Aduhelm, would be covered for people with Medicare only if they are enrolled in qualifying clinical trials. Dr. Jason Karlawish joins the podcast to discuss the recent proposal, share his reaction to the decision, and tell us how this coverage policy could impact the development of other Alzheimer’s disease treatments in the future.
Guest: Jason Karlawish, MD, co-director, Penn Memory Center, professor of medicine, medical ethics and health policy, and neurology, University of Pennsylvania
Episode Topics1:48 What’s the difference between the FDA and Centers for Medicare and Medicaid Services?
3:58 What is the purpose of sharing a proposal and allowing public comment after? Is it possible the proposal could change?
9:09 What are your key takeaways from the CMS proposal?
11:58 Who’s being charged the cost of the treatment if it is part of a clinical trial?
18:33 What does this decision, with its focus on research often occurring in major urban medical centers, mean for equity and access?
26:27 What is the future of Alzheimer’s disease research after the CMS decision?
Show NotesRead the Center for Medicare and Medicaid Services’s press release about the proposed coverage policy, view submitted public comments about the decision, and submit your own comment.
Learn more about Dr. Jason Karlawish’s work and writing at his website.
Listen to our four-part episode series with Dr. Jason Karlawish about his book, The Problem of Alzheimer’s, on our website (episode 1, episode 2, episode 3, episode 4).
Study Shows APOE Gene Affects Hispanic Populations’ Risk of Cognitive Decline Differently to Non-Hispanic Populations
Putting Lecanemab into Practice: A Clinician’s Perspective on the New Alzheimer’s Treatment
Deciding to Donate: Barriers and Benefits of Brain Donations for Diverse Populations
Lecanemab, Clinical Trials, and the Importance of Clinical Meaningfulness
Understanding the Social Determinants of Health and Disparities in Alzheimer’s Research
Take Care of Your MIND: Reviewing the MIND Diet for Healthy Brain Aging
The National Strategy for Diversifying Alzheimer’s Research
The Future of Neuroscience: Early-Career Researchers Named ’One to Watch’ by the Alzheimer’s Association
Studies Look at Generational Differences and Associations between Cognition, Sensory Changes and Blood Biomarkers
Disclosing Alzheimer’s Disease Biomarker Results in Diverse Populations
Difficult but Beneficial Conversations about End-of-Life Care
Caregiving While Black: Dementia Care for Different Racial and Ethnic Groups
Our Evolving Understanding of Mild Cognitive Impairment
A Closer Look at the Lecanemab Clinical Trials
Therapeutic Fibbing: Mastering the Art of Communicating with a Loved One with Dementia
The Future of the Alzheimer’s Association: Interview with Dr. Joanne Pike and Harry Johns
Introducing Lecanemab, the Latest Alzheimer’s Disease Drug to Receive FDA Accelerated Approval
Healthy Habits for the New Year and Modifiable Risk Factors for Alzheimer’s Disease
Bioenergetics: How Mitochondria Affects Alzheimer’s Disease and Aging
Looking Toward the Future: How Preclinical Alzheimer’s Disease Biomarker Disclosures Impact Society
Create your
podcast in
minutes
It is Free
Good Mood Revolution
Life in the A-Zone
Caregiver Storyteller - About Alzheimer’s and Dementia Caregiving
The Life, Love, and Alzheimer’s Podcast
Fading Memories: Alzheimer’s/Dementia Caregiver Support
Alzheimer’s Speaks